Prevalence of hypogonadism in males aged at least 45 years: the HIM study

T Mulligan, M F Frick, Q C Zuraw, A Stemhagen, C McWhirter, T Mulligan, M F Frick, Q C Zuraw, A Stemhagen, C McWhirter

Abstract

The Hypogonadism in Males study estimated the prevalence of hypogonadism [total testosterone (TT) < 300 ng/dl] in men aged > or = 45 years visiting primary care practices in the United States. A blood sample was obtained between 8 am and noon and assayed for TT, free testosterone (FT) and bioavailable testosterone (BAT). Common symptoms of hypogonadism, comorbid conditions, demographics and reason for visit were recorded. Of 2162 patients, 836 were hypogonadal, with 80 receiving testosterone. Crude prevalence rate of hypogonadism was 38.7%. Similar trends were observed for FT and BAT. Among men not receiving testosterone, 756 (36.3%) were hypogonadal; odds ratios for having hypogonadism were significantly higher in men with hypertension (1.84), hyperlipidaemia (1.47), diabetes (2.09), obesity (2.38), prostate disease (1.29) and asthma or chronic obstructive pulmonary disease (1.40) than in men without these conditions. The prevalence of hypogonadism was 38.7% in men aged > or = 45 years presenting to primary care offices.

Figures

Figure 1
Figure 1
Total testosterone concentrations
Figure 2
Figure 2
Sampling time and total testosterone concentrations for enrolled patients
Figure 3
Figure 3
Age-specific prevalence of hypogonadism for enrolled patients
Figure 4
Figure 4
Body mass index vs. total testosterone for enrolled patients

References

    1. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients – 2002 update. Endocr Pract. 2002;8:440–56.
    1. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89:3813–7.
    1. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589–98.
    1. Delhez M, Hansenne M, Legros JJ. Andropause and psychopathology: minor symptoms rather than pathological ones. Psychoneuroendocrinology. 2003;28:863–74.
    1. Shores MM, Sloan KL, Matsumoto AM, et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162–7.
    1. Szulc P, Claustrat B, Marchand F, et al. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab. 2003;88:5240–7.
    1. McLachlan RI, Allan CA. Defining the prevalence and incidence of androgen deficiency in aging men: where are the goal posts. J Clin Endocrinol Metab. 2004;89:5916–9.
    1. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920–6.
    1. Vermeulen A. Androgen replacement therapy in the aging male – a critical evaluation. J Clin Endocrinol Metab. 2001;86:2380–90.
    1. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–31.
    1. Lethbridge-Cejku M, Schiller J, Berndel L. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2002. Vital Health Stat 10. 2004;222:1–151.
    1. Population Division US Census Bureau. Table 2: Annual estimates of the population by sex and selected age groups for the United States: April 1, 2000 to July 1, 2003 (NC-EST2003–02) 2005. [16 December 2005]. .
    1. Belanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 1994;79:1086–90.
    1. Gray A, Feldman HA, McKinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016–25.
    1. Morley JE, Kaiser FE, Perry HM, 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410–3.
    1. Gapstur SM, Gann PH, Kopp P, et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev. 2002;11:1041–7.
    1. Kubricht WS, 3rd, Williams BJ, Whatley T, et al. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology. 1999;54:1035–8.
    1. Asbell SO, Raimane KC, Montesano AT, et al. Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients. J Natl Med Assoc. 2000;92:445–9.
    1. Amatruda JM, Harman SM, Pourmotabbed G, et al. Depressed plasma testosterone and fractional binding of testosterone in obese males. J Clin Endocrinol Metab. 1978;47:268–71.
    1. Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929–31.
    1. Centers for Disease Control. About minority health. 2005. [16 December 2005]. .
    1. Brambilla DJ, McKinlay SM, McKinlay JB, et al. Does collecting repeated blood samples from each subject improve the precision of estimated steroid hormone levels. J Clin Epidemiol. 1996;49:345–50.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner